Cablivi for Acquired Thrombotic Thrombocytopenic purpura
What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.
Cablivi (caplacizumab-yhdp, Sanofi Genzyme)
Indications: Treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy
Dosage:
- Day 1 of treatment: 11-mg bolus intravenous injection at least 15 min prior to plasma exchange, followed by 11-mg subcutaneous injection after plasma exchange
- 11-mg subcutaneous injection once daily for 30 days following plasma exchange
- Treatment may be extended for a maximun of 28 days only if persistent underlying diseases remain present
- Discontinue if two or more recurrences of aTTP occur while on Cablivi
Contraindications: Previous severe hypersensitivity reaction to caplacizumab-yhdp or any of the excipients.
Recent Videos
